208 related articles for article (PubMed ID: 33076275)
1. Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care.
Ajaka L; Heil E; Schmalzle S
Antibiotics (Basel); 2020 Oct; 9(10):. PubMed ID: 33076275
[TBL] [Abstract][Full Text] [Related]
2. Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections.
Bork JT; Heil EL; Berry S; Lopes E; Davé R; Gilliam BL; Amoroso A
Infect Dis Ther; 2019 Jun; 8(2):171-184. PubMed ID: 31054088
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin as an alternative to traditional outpatient parenteral antimicrobial therapy for deep gram-positive infections - an observational, retrospective review.
Bao H; Igwilo-Alaneme R; Sonia F; Cowman K; Kahn M; Nori P
Ther Adv Infect Dis; 2024; 11():20499361241245523. PubMed ID: 38645297
[TBL] [Abstract][Full Text] [Related]
5. The hidden cost of dalbavancin: OPAT RN time required in coordination for persons who use drugs.
Douglass AH; Mayer H; Young K; Sikka MK; Strnad L; Makadia J; Sukerman E; Lewis JS; Streifel AC
Ther Adv Infect Dis; 2023; 10():20499361231189405. PubMed ID: 37581105
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Use of Dalbavancin for Off-Label Indications.
Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
[TBL] [Abstract][Full Text] [Related]
7. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years.
Salinas-Botrán A; Olmos-Blanco C; Fernández de Velasco-Pérez D; Guzmán-Carreras A; Morales-Rosas A; Gómez-Ramírez D
Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; ():. PubMed ID: 38763866
[TBL] [Abstract][Full Text] [Related]
8. A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by
Teigell-Muñoz FJ; Mateos-González M; Bernal Hertfelder E; Sánchez de Torre A; García-Ferrón M; de Cáceres Velasco C; Bueno Muiño C
Eur J Case Rep Intern Med; 2023; 10(1):003654. PubMed ID: 36819647
[TBL] [Abstract][Full Text] [Related]
9. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study.
Krsak M; Scherger S; Miller MA; Cobb V; Montague BT; Henao-Martínez AF; Molina KC
Ther Adv Infect Dis; 2024; 11():20499361231223889. PubMed ID: 38249543
[TBL] [Abstract][Full Text] [Related]
10. Outcomes According to Discharge Location for Persons Who Inject Drugs Receiving Outpatient Parenteral Antimicrobial Therapy.
D'Couto HT; Robbins GK; Ard KL; Wakeman SE; Alves J; Nelson SB
Open Forum Infect Dis; 2018 May; 5(5):ofy056. PubMed ID: 29766017
[TBL] [Abstract][Full Text] [Related]
11. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series.
Evins C; Lancaster H; Schnee AE
Ann Clin Microbiol Antimicrob; 2022 Apr; 21(1):16. PubMed ID: 35473711
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
Hakim A; Braun H; Thornton D; Strymish J
Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
[TBL] [Abstract][Full Text] [Related]
13. Three-years of dalbavancin use at a UK tertiary referral hospital serving a population with high numbers of people who inject drugs.
Bresges C; Bresges K; Hewitt C; Sharma S; Davies B
JAC Antimicrob Resist; 2024 Jun; 6(3):dlae066. PubMed ID: 38716401
[TBL] [Abstract][Full Text] [Related]
14. Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin.
Cho JC; Estrada SJ; Beltran AJ; Revuelta MP
J Clin Pharm Ther; 2015 Oct; 40(5):604-606. PubMed ID: 26183753
[TBL] [Abstract][Full Text] [Related]
15. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
Rebold N; Alosaimy S; Pearson JC; Dionne B; Taqi A; Lagnf A; Lucas K; Biagi M; Lombardo N; Eudy J; Anderson DT; Mahoney MV; Kufel WD; D'Antonio JA; Jones BM; Frens JJ; Baumeister T; Geriak M; Sakoulas G; Farmakiotis D; Delaportas D; Larew J; Veve MP; Rybak MJ
Infect Dis Ther; 2024 Mar; 13(3):565-579. PubMed ID: 38427289
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.
Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
Drugs Context; 2018; 7():212559. PubMed ID: 30574170
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis.
Suárez M; Pérez-Landeiro A; Sanjurjo A; Lima O; Sousa A; López A; Martínez-Lamas L; Cabrera X; Rubianes M; Pérez-Rodríguez MT
Int J Infect Dis; 2024 Jan; 138():41-45. PubMed ID: 37931892
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy.
Tuan JJ; Kayani J; Fisher A; Kotansky B; Dembry LM; Datta R
Antimicrob Steward Healthc Epidemiol; 2022; 2(1):e83. PubMed ID: 36483361
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin as a Viable Alternative for Addressing Treatment Adherence in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: A Case Report.
Sabina M; Cobian J; Dibo I
Cureus; 2024 Feb; 16(2):e54078. PubMed ID: 38481906
[TBL] [Abstract][Full Text] [Related]
20. Outpatient parenteral antibiotic therapy for infective endocarditis: a review of 4 years' experience at a UK centre.
Partridge DG; O'Brien E; Chapman AL
Postgrad Med J; 2012 Jul; 88(1041):377-81. PubMed ID: 22366395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]